Cancer Family
Rare Neoplasm
CI-CAN-00000048Explore in graph →
Non-malignant116 active trials3 approved drugs7 evidence items
- NCIt
- C7201
Loading cancer entity…
Cancer Family
CI-CAN-00000048Explore in graph →
Clinical trials
361 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03213665 | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Apr 13, 2026 | clinicaltrials |
| NCT07211230 | Collagenase Biobank Study | not yet recruiting | — | 107 | University of ChicagoOTHER | 1 | Apr 9, 2026 |
| NCT05286788 | MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma | recruiting | Phase 2 | 38 | Nationwide Children's HospitalOTHER | 3 | Apr 8, 2026 | clinicaltrials |
| NCT07511114 | A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping | not yet recruiting | Phase 3 | 156 | Ruijin HospitalOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07512726 | DevelopmentA Web-Based Support Care Program for Individuals Diagnosed With Colorectal Cancer | completed | N/A | 24 | Ilknur YaziciogluOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03526250 | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 2 | Apr 3, 2026 | clinicaltrials |
| NCT06327685 | Avapritinib With Decitabine in Patients With SM-AHN | recruiting | Phase 1 | 34 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT03401060 | Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis(DenosuMast) | completed | Phase 3 | 24 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT02450396 | Pregnancy and Medically Assisted Conception in Rare Diseases(EGR2) | withdrawn | — | 0 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06481826 | Glofitamab in Chinese Patients With R/R DLBCL | recruiting | — | 20 | Peking Union Medical College HospitalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07481110 | Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Gastric Cancers in Algeria(ECLIPSE-CG) | recruiting | — | 1,000 | Société Algérienne de Formation et Recherche en OncologieOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT03610906 | Prospective Pilot Study Identifying Clinically Relevant Biological Targets for Medical Therapy | enrolling by invitation | — | 250 | University of Colorado, DenverOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07472621 | Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma | not yet recruiting | — | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07474025 | Integrating Peritoneal Histological Growth Patterns Into Preoperative Decision-Making for Colorectal Peritoneal Metastses | not yet recruiting | — | 30 | Jules Bordet InstituteOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT03404193 | Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome | terminated | Phase 2 | 235 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07447050 | Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial | recruiting | Phase 2 | 24 | University of California, IrvineOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06896370 | An Observational Study for Gastric Cancer in Carriers of High Risk Helicobacter Pylori | recruiting | — | 3,000 | Fudan UniversityOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06943794 | Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial | not yet recruiting | N/A | 4,824 | Fudan UniversityOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06943807 | Prospective Gastric Cancer Screening With Fecal Multi-target DNA Analysis | recruiting | — | 15,000 | Fudan UniversityOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT04134559 | Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma | recruiting | Phase 2 | 18 | Allison O'Neill, MDOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT07301554 | Food Preferences and Craniopharyngiomas(PREFAMHYPO) | not yet recruiting | — | 346 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04907643 | Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes | recruiting | N/A | 360 | Cedars-Sinai Medical CenterOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT03970226 | Tocilizumab in Children With ACP | active not recruiting | Early Phase 1 | 9 | University of Colorado, DenverOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06748001 | Avapritinib Rollover Study | recruiting | Phase 4 | 60 | Blueprint Medicines CorporationINDUSTRY | 6 | Feb 9, 2026 | clinicaltrials |
| NCT05093335 | In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET | recruiting | Early Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07389356 | Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL | not yet recruiting | N/A | 70 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Feb 5, 2026 | clinicaltrials |
| NCT03485547 | Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | completed | Phase 1 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT01199562 | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | active not recruiting | — | 153 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT04681105 | Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies | completed | Phase 1 | 13 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07371663 | An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 266 | Beijing Tide Pharmaceutical Co., LtdINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07361107 | Evaluation of Circulating Immune Response After Histosonics in Colorectal Cancer (ECHO-CRC)(ECHO CRC) | recruiting | Phase 1 | 12 | Northwell HealthOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07356466 | Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma(FUGES032) | enrolling by invitation | Early Phase 1 | 100 | Fujian Medical UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07342686 | Hypothalamic-Stratified Nursing Pathway for Pediatric Craniopharyngioma | completed | — | 500 | West China HospitalOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT06573723 | Institutional Registry of Rare Diseases | recruiting | — | 380 | Hospital Italiano de Buenos AiresOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07334431 | Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer | recruiting | Phase 1 / Phase 2 | 45 | Henan Cancer HospitalOTHER_GOV | 1 | Jan 12, 2026 | clinicaltrials |
| NCT07328178 | Analysis of the Role of IgE Proteoforms in Health and Disease(IgE-PhD) | recruiting | — | 200 | KU LeuvenOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07288879 | DALY II Japan/MB-CART2019.1 for DLBCL(DALY II Japan) | recruiting | Phase 2 | 31 | Miltenyi Biomedicine GmbHINDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07326371 | Glofitamab Combined With CAR-T Therapy in R/R DLBCL | not yet recruiting | Phase 2 | 24 | Ruijin HospitalOTHER | 0 | Jan 8, 2026 | clinicaltrials |
| NCT07312500 | Fecal DNA Methylation and Helicobacter Pylori SNPs Tests for Gastric Cancer | active not recruiting | — | 3,000 | Fudan UniversityOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT00255346 | Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) | completed | Phase 2 | 68 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT07306962 | Virtual Lesion Segmentation and Mandibular Ameloblastoma Radiographic Safety Margin | recruiting | N/A | 10 | Alexandria UniversityOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT07307053 | Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) | not yet recruiting | Phase 1 / Phase 2 | 600 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Dec 29, 2025 | clinicaltrials |
| NCT01048281 | Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma | recruiting | — | 100 | Stanford UniversityOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05950802 | Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta(ODIN) | recruiting | Phase 1 | 40 | University Health Network, TorontoOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT07255963 | Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL | recruiting | Phase 2 | 29 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT05051046 | Colorectal Cancer Screnning Colonoscopy Under Hypnosis(CODEPICCH) | recruiting | N/A | 600 | University Hospital, ToursOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07231250 | Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma | not yet recruiting | Phase 2 | 40 | Li ZhimingOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT06272461 | Comparison of Intravenous Lidocaine vs Ketamine in Colorectal Surgery | recruiting | N/A | 50 | University Tunis El ManarOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06970145 | Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma | recruiting | Phase 1 / Phase 2 | 57 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 18, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Apr 13, 2026source: clinicaltrials